Full dose forever, a lower maintenance dose, or nothing at all — until this year, no trial had actually tested the middle option. SURMOUNT-MAINTAIN is the first dedicated study of dose reduction after weight loss on tirzepatide.
Anyone who reaches their goal weight on Mounjaro or Zepbound eventually has this conversation with a prescriber: keep the full dose indefinitely, taper to something lower, or stop altogether. The discontinuation data — from SURMOUNT-4 — already showed that stopping tends to bring weight back. What was missing was a controlled answer to the question in between: does a lower maintenance dose actually hold the line, or is it just a slower version of stopping?
SURMOUNT-MAINTAIN, published in The Lancet in May 2026, is the first randomized trial built specifically to answer that.
441 adults with obesity (mean weight 113.8 kg, mean BMI 40.1) first went through a 60-week open-label run-in on tirzepatide at the maximum tolerated dose — 10 or 15 mg weekly. The 378 who had lost at least 5% of their body weight and tolerated 10 mg or more were then randomized into three arms for a further 52 weeks:
All three groups kept receiving diet and activity counseling throughout. Rescue tirzepatide was allowed from 24 weeks after randomization for anyone who regained more than half of what they'd lost — so this measures maintenance under realistic clinical safety nets, not a trial designed to watch people regain weight unchecked.
At week 112, total weight loss from the original baseline was −21.9% for those who stayed on full dose, −16.6% for the 5 mg group, and −9.9% for placebo. Regaining half or more of the lost weight happened in just 8% of the full-dose group and 25% of the 5 mg group — versus 67% on placebo.
Sources: Horn et al., The Lancet, published online May 12, 2026 (SURMOUNT-MAINTAIN), doi:10.1016/S0140-6736(26)00656-2 · ACC.org trial summary.
5 mg is a real middle option, not a placebo with extra steps. The 5 mg group kept off roughly three-quarters of their original weight loss and still beat placebo by a wide, statistically significant margin on weight, waist circumference, blood pressure, and lipids. It's a meaningfully different outcome from stopping.
It isn't equivalent to staying at full dose. The full-dose group preserved more weight loss and more of the cardiometabolic gains — reductions in BMI, waist size, blood pressure, and triglycerides were all larger at 10–15 mg than at 5 mg. Among participants with prediabetes, normal blood sugar was reached more often at full dose too.
Side effects didn't disappear at the lower dose. GI symptoms — mostly mild to moderate nausea and related issues — were still more common on tirzepatide than placebo during the maintenance period, at both doses. Serious adverse events were rare across all three arms.
This is exactly the kind of decision — what dose, starting when — that's easy to lose track of if you're managing it manually. Whether a prescriber has someone stepping down to a lower maintenance dose or holding at max, GLP1ShotDay logs the actual dose taken each week, so the record matches what really happened rather than what the original plan said.
This article summarizes a published clinical trial for general education. It is not medical advice. Any change to a tirzepatide dose — up, down, or stopping — should be made with a prescriber, not on your own.